Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
May 13, 2020 at 03:08 pm EDT
Share
Genovate Biotechnology Co., Ltd. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was TWD 135.835 million compared to TWD 135.356 million a year ago. Operating income was TWD 19.302 million compared to TWD 26.264 million a year ago. Net income was TWD 18.579 million compared to TWD 23.522 million a year ago. Basic earnings per share was TWD 0.18 compared to TWD 0.22 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 